Breaking News:-

DCGI approves anti-Covid drug developed by DRDO for emergency use

NEW DELHI: The Drugs Controller General of India (DCGI) has approved the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 patients.

The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy's Laboratories, Hyderabad.

"Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients," DRDO said in an official statement on Saturday.

"In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production," the statement added.

 

Fast, accurate and updated real time local news is available on your smartphone and tablet.
STAY CONNECTED EVERYWHERE YOU GO!

Author

Jammu Links News